Galectin-3 Biomarker Monitoring for CRT Patient Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cardiac resynchronization therapy (CRT) devices have a high failure rate in treating congestive heart failure patients, with about 30% of patients not responding to treatment, and there is a need for better criteria to identify optimal candidates and monitor treatment efficacy.
Innovation Solution
Monitoring galectin-3 concentrations in body fluids, such as blood or plasma, to predict and assess the responsiveness of heart failure patients to CRT, allowing for personalized treatment decisions and identifying patients likely to benefit from CRT devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cardiac resynchronization therapy (CRT) devices are implanted in heart failure patients, then quality of life and mortality are improved in some patients, but about 30% of patients fail to respond to treatment
Solution Approach 1:
The patent applies preliminary action by measuring galectin-3 concentrations before CRT device implantation to predict which patients will respond to treatment. This pre-assessment allows clinicians to identify suitable candidates in advance, avoiding ineffective treatments for non-responders and improving overall treatment reliability.
2Measurement precision
If galectin-3 concentration measurements are performed to predict CRT responsiveness, then treatment selection accuracy is improved, but additional testing time and complexity are required
Solution Approach 1:
The patent replaces complex clinical assessment procedures with a biochemical measurement system. Instead of relying on multiple clinical evaluations and subjective assessments to predict CRT responsiveness, the invention uses galectin-3 concentration measurements, which can be performed using standardized laboratory techniques, thereby simplifying the overall testing procedure while improving selection accuracy.
3Loss of information
If galectin-3 levels are monitored over time in CRT patients, then disease progression and treatment efficacy can be tracked, but additional monitoring procedures and costs are incurred
Solution Approach 1:
The patent implements feedback by monitoring galectin-3 concentrations at multiple time points (baseline, 3 months, 6 months, 12 months, and 18 months) after CRT implantation. These measurements provide continuous information about treatment response and disease progression, allowing clinicians to adjust therapy based on actual patient response. The systematic feedback loop enables early identification of non-responders and optimization of treatment strategies.
Data Source
AI summary
The present invention relates to materials and methods for monitoring and predicting a heart failure patient's physiological response to cardiac resynchronization therapy. More specifically, the present invention relates to the endogenous protein galectin-3 and its use in monitoring progression of disease in a patient undergoing cardiac resynchronization therapy, and as a predictor of response to cardiac resynchronization therapy.